As part of its efforts to build the leading platform for cell programming and biosecurity, Constric by Ginkgo, a division of Ginkgo Bioworks (NYSE: DNA), today announced it had entered into a Co-Marketing Agreement with Illumina, Inc., a company that is building the world's leading platform for cell programming and biosecurity. In order to expand biosecurity capabilities globally, the company (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies, is partnering with it.
In countries around the world, Concentric is building a global pathogen monitoring network, referred to as a "bioradar system," to help detect, characterize, and respond to biological threats in an informed manner and to support informed decision-making in the pursuit of global health objectives.. As more than a dozen countries are actively scoping and implementing biosecurity programs with Concentric's platform of integrated services, the Bioradar network can play a significant role in strengthening the country's security as well as its early warning capability.. As one of the world's leading providers of DNA sequencing and array-based technologies, Illumina serves customers across a range of fields, including research, clinical, and applied science. Using the leading next-generation sequencing instruments, consumables, and software from Illumina, researchers are able to understand pathogens in a way that has never been possible before. In order to enable stakeholders to fully understand the threats that are circulating in the world today, these solutions can be used to interrogate many different types of specimens, including
In order to enable stakeholders to fully understand the threats that are circulating in the world today, these solutions can be used to interrogate many different types of specimens, including
In the agreement, the partners intend to demonstrate the use of Illumina products in conjunction with Concentric's bioradar, to facilitate the expansion of the pathogen monitoring network in a way that empowers countries and to expand the scope and scale of global pathogen genomic surveillance, among other things. In order to improve early warnings of emerging and novel pathogens, as well as fill gaps in global biosurveillance infrastructure, Concentric and Illumina are joining forces to market their solutions.
We remain deeply vulnerable to the next novel pathogen threat if sustained investments in global early detection are not made". Through this relationship with Illumina, Concentric aims to accelerate deployment of our early warning and bioradar programs for governments around the world as they seek to modernize defenses against biological threats," said Matt McKnight, General Manager for Biosecurity at Ginkgo Bioworks.. The creation of a sustained genomic monitoring capacity is urgently required so that risks can be identified and collective responses can be initiated ahead of potential pandemics and emerging biothreats'
The creation of a sustained genomic monitoring capacity is urgently required so that risks can be identified and collective responses can be initiated ahead of potential pandemics and emerging biothreats'

Source prnewswire